Overall, these findings are in support of previous work showing that melanoma cells are more sensitive to MEK inhibition than normal cells, with drug sensitivity to selumetinib in the same range as detected here (as previously reviewed [35]). The gene discussed is MAP2K7; the disease is melanoma.